82 related articles for article (PubMed ID: 11826487)
1. [Results of a phase I clinical trial of "theraphthal + ascorbic acid" catalytic system].
Garin AM; Gorbunova VA; Gershanovich ML; Manziuk LV; Borodkina AG; Breder VV; Karmanovskaia OB; Zubrikhina GN; Madzhuga AV; Zimakova NI; Trapeznikov NN
Vopr Onkol; 2001; 47(6):676-9. PubMed ID: 11826487
[TBL] [Abstract][Full Text] [Related]
2. [Preclinical toxicological study of theraphthal-Lio and binary catalytic system "theraphthal-Lio+ascorbic acid"].
Mikhaĭlova LM; Koniaeva ON; Chlenova EL; Merkulova IB; Ermakova NP; Gavrilova TN; Sergeev AA
Vopr Onkol; 2001; 47(6):695-700. PubMed ID: 11826491
[TBL] [Abstract][Full Text] [Related]
3. [Toxicity of binary "theraphthal-Lio+ascorbic acid" (TPH+AA) catalytic system during different methods of regional intra-arterial administration in dogs].
Mikhaĭlova LM; Merkulova IB; Ermakova NP; Koniaeva OI; Chlenova EL; Zontov SV; Sergeev AA
Vopr Onkol; 2001; 47(6):710-4. PubMed ID: 11826494
[TBL] [Abstract][Full Text] [Related]
4. [Effects of theraphthal-Lio on hemostasis in experimental animals].
Madzhuga AV; Ermakova NP; Chlenova EL; Koniaeva ON; Somonova OV; Elizarova AL; Mikhaĭlova LM
Vopr Onkol; 2001; 47(6):715-7. PubMed ID: 11826495
[TBL] [Abstract][Full Text] [Related]
5. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
6. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912
[TBL] [Abstract][Full Text] [Related]
10. Postsurgical adjuvant chemotherapy: a review.
Diekamp U; Lad TE; McGuire WP
Surg Annu; 1981; 13():31-52. PubMed ID: 7025285
[No Abstract] [Full Text] [Related]
11. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
13. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
Goffin J; Baral S; Tu D; Nomikos D; Seymour L
Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
15. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C
Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
17. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
18. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
19. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]